方法：计算机检索PubMed、EMbase、Cochrane Library、维普中文科技期刊数据库、中国知网、万方数据库，查找国内外应用奥洛他定滴眼液联合治疗比较单独奥洛他定治疗过敏性结膜炎患者的随机对照试验(RCT)，检索时限截至 2016-08。国外未查到相关文献。根据纳入与排除标准纳入可分析的数据，采用 Review Manager 5.3软件进行 Meta 分析。

结果：最终纳入 28 个 RCT，共计3 568例患者，其中治疗组 1 799例，对照组1 769例。Meta 分析结果显示：应用奥洛他定滴眼液联合治疗过敏性结膜炎的临床疗效均优于奥洛他定滴眼液单独治疗，其差异均有统计学意义[OR=3.54，95%CI(2.71～4.61)，P<0.001]。

结论：应用奥洛他定滴眼液联合治疗过敏性结膜炎患者可使症状与体征显著改善，提高治疗的有效率。受纳入研究质量和数量所限，上述结论尚需进一步开展严格设计的随机双盲对照试验加以验证。

METHODS: We performed a comprehensive search for the randomized controlled trials(RCTs)about the olopatadine eye drops and other therapies vs. olopatadine eye drops monotherapy for treating allergic conjunctivitis published by April, 2016 from PubMed, EMbase, Cochrane Library, VIP Chinese periodical Database, CNKI and Wan Fang Chinese periodical Database. Studies obtained from eligible database were filtered according to the criteria, and data were retrieved from those studies for further analysis. Then we performed a Meta-analysis using RevMan 5.3 software.

RESULTS: A total of 28 RCTs were included. Among all 3568 patients involved in, 1 799 were in the treatment group, while the other 1 769 were in the control group. The results of Meta-analysis showed that the olopatadine eye drops and other therapies was superior to monotherapy for patients with allergic conjunctivitis in clinical effects \〖OR=3.54,95%CI(2.71,4.61),P<0.001\〗.

CONCLUSION: The existing evidence supports that the prognosis of the olopatadine eye drops and other therapies is better than olopatadine eye drops monotherapy for treating allergic conjunctivitis. For the quality and quantity limitations of the included studies, more well-designed and double blind RCTs are required to further prove this conclusion.